Obtaining evidence of genetic changes to make a cancer diagnosis usually requires a biopsy, which can be problematic for sensitive regions of the body such as the lungs. Based on recent review of patients with lung cancer, researchers have found that scanning the tumor cells with quantitative computed tomography based texture analysis (QTA) determines (with 90% accuracy) whether the patient's tumor had a cancer-causing gene mutation.
Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell’s natural defenses and efficiently insert disease-fighting genes into the cell’s genome. In a new study, a team of researchers report that the drug rapamycin, which is commonly used to slow cancer growth, enables delivery of a therapeutic dose of genes to blood stem cells while preserving stem cell function.
3-D mammograms may be better at finding cancer than regular scans, a large study suggests, although whether that means saving more lives isn't known. The study involved almost half a million breast scans, with more than one-third of them using relatively new 3-D imaging along with conventional scans. The rest used regular mammograms alone.
Current drug delivery systems used to administer chemotherapy to cancer patients typically release a constant dose of the drug over time, but a new study challenges this "slow and steady" approach and offers a novel way to locally deliver the drugs "on demand," as reported in the Proceedings of the National Academy of Sciences.
Lung cancer causes more deaths in the U.S. than the next three most common cancers combined, and the main reason is poor detection methods. A new device developed by a team of Israeli, American and British cancer researchers may turn the tide by both accurately detecting lung cancer and identifying its stage of progression. The breathalyzer test is embedded with a "NaNose" nanotech chip to literally "sniff out" cancer tumors.
Nanoengineers at UC San Diego have developed a nanoshell to protect foreign enzymes used to starve cancer cells as part of chemotherapy. Enzymes are naturally smart machines that are responsible for many complex functions and chemical reactions in biology. However, despite their huge potential, their use in medicine has been limited by the immune system, which is designed to attack foreign intruders.
A bold new way to test cancer drugs started Monday. Like a medical version of speed dating, doctors will sort through multiple experimental drugs and match patients to the one most likely to succeed based on each person's unique tumor gene profile. Five drug companies, the government, private foundations and advocacy groups are taking part.
Researchers have developed nanoparticles that not only bypass the body’s defence system, but also find their way to the diseased cells. The procedure uses fragments from a particular type of antibody that only occurs in camels and llamas. The small particles were even successful under conditions which are very similar to the situation within potential patients’ bodies.
Women who often indulge their cravings for hamburgers, steaks and other red meat may have a slightly higher risk of breast cancer, a new study suggests. Doctors have long warned that a diet loaded with red meat is linked to cancers including those of the colon and pancreas, but there has been less evidence for its role in breast cancer.
Sometimes a cell has to die—when it's done with its job or inflicted with injury that could otherwise harm an organism. Conversely, cells that refuse to die when expected can lead to cancer. So scientists interested in fighting cancer have been keenly interested in learning the details of "programmed cell death." They want to understand what happens when this process goes awry and identify new targets for anticancer drugs.
Scientists from Lawrence Berkeley National Laboratory have gained more insights into why older women are more susceptible to breast cancer. They found that as women age, the cells responsible for maintaining healthy breast tissue stop responding to their immediate surroundings, including mechanical cues that should prompt them to suppress nearby tumors.
Short, customized carbon nanotubes have the potential to deliver drugs to pancreatic cancer cells and destroy them from within, according to researchers at Rice Univ. and the Univ. of Texas MD Anderson Cancer Center. Pristine nanotubes produced through a new process developed at Rice can be modified to carry drugs to tumors through gaps in blood-vessel walls that larger particles cannot fit through.
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. The disease can be caused by both external and internal factors; and, if the spread isn’t controlled, it can result in death. The annual cancer statistics report from the American Cancer Society estimates there will be 1,885,540 new cancer cases and 585,720 cancer deaths in the U.S. for 2014.
The first preclinical study of a new Rice Univ.-developed anticancer technology found that a novel combination of existing clinical treatments can instantaneously detect and kill only cancer cells without harming surrounding normal organs. The research reports that Rice’s “quadrapeutics” technology was 17 times more efficient than conventional chemoradiation therapy against aggressive, drug-resistant head and neck tumors.
Developmental biologists at Tufts Univ., using a tadpole model, have shown that bioelectrical signals from distant cells control the incidence of tumors arising from cancer-causing genes and that this process is impacted by levels of a common fatty acid produced by bacteria found in the tadpole and also in humans.
Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anticancer drugs and are capable of introducing a “cocktail” of multiple drugs into cancer cells. The researchers are all part the joint biomedical engineering program at North Carolina State Univ. and the Univ. of North Carolina at Chapel Hill.
A pathway to the design of even more effective versions of the powerful anticancer drug Taxol has been opened with the most detailed look ever at the assembly and disassembly of microtubules, tiny fibers of tubulin protein that form the cytoskeletons of living cells and play a crucial role in mitosis.
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration for clinical trials in cancer patients. The new report, published in Angewandte Chemie, focuses on a compound called TIC10.
A new “lab-on-a-chip” platform developed at the Institute of Photonic Sciences in Spain is capable of detecting detect very low concentrations of protein cancer markers, enabling diagnoses of the disease in its earliest stages. The device, just a few square centimeters in size, uses recent advances in plasmonics, nano-fabrication, microfluids and surface chemistry.
Harvard Stem Cell Institute scientists have a potential solution for how to more effectively kill tumor cells using cancer-killing viruses. The investigators report that trapping virus-loaded stem cells in a gel and applying them to tumors significantly improved survival in mice with glioblastoma multiforme, the most common brain tumor in human adults and also the most difficult to treat.
Photodynamic therapy (PDT) is an effective treatment for easily accessible tumors such as oral and skin cancer. But the procedure, which uses lasers to activate special drugs called photosensitizing agents, isn’t adept at fighting cancer deep inside the body. That could change because of a new technology that could bring PDT into areas of the body which were previously inaccessible.
Fluorescent proteins have helped researchers open doors to countless molecular imaging applications and deepened our understanding of biological processes. Without fluorescence, advancements in oncology, drug discovery and any field that requires single-cell to whole-body imaging would be substantially limited.
Biomedical engineering researchers have developed an anti-cancer drug delivery method that essentially smuggles the drug into a cancer cell before triggering its release. The method can be likened to keeping a cancer-killing bomb and its detonator separate until they are inside a cancer cell, where they then combine to destroy the cell.
Massachusetts Institute of Technology researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage. In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast tumors.
From time to time, genetic codes aren’t copied and collated properly, leaving gaps or breaks. A comprehensive mapping of these “fragile sites” in yeast by a team of Duke Univ. researchers shows that errors appear in specific areas of the genome where the DNA-copying machinery is slowed or stalled. The study could shed light on abnormalities seen in solid tumors.